Results 21 to 30 of about 26,327 (353)

Synthesis and Biological Evaluation of Hydroxylated Monocarbonyl Curcumin Derivatives as Potential Inducers of Neprilysin Activity

Biomedicines, 2021
Background: Alzheimer’s disease (AD) involves impairment of Aβ clearance. Neprilysin (NEP) is the most efficient Aβ peptidase. Enhancement of the activity or expression of NEP may provide a prominent therapeutic strategy against AD.
Dimitris Matiadis, See-Ting Ng, Eric H.-L. Chen, Georgia Nigianni, Veroniki P. Vidali, Aleksander Canko, Rita P.-Y. Chen, Marina Sagnou   +7 more
doaj   +1 more source

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources

Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?

Neural Regeneration Research, 2022
Neurodegenerative brain disorders are a major burden in our society, such as Alzheimer´s disease. In order to repair or prevent such diseases, drugs are designed which enter the brain, but the blood-brain barrier limits their entry and the search for ...
Christian Humpel
doaj   +1 more source

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure

Медицинский совет, 2020
The article describes the possibility of using a new class of angiotensin II/neprilysin receptor inhibitor - sacubitrile/valsartan for the treatment of chronic heart failure (CHF). The role of the natriuretic peptide system in the pathogenesis of CHF and
V. S. Nikiforov
doaj   +1 more source

Neprilysin as a Biomarker: Challenges and Opportunities

Cardiac Failure Review, 2020
Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care.
Pavo, Noemi, Prausmüller, Suriya, Bartko, Philipp E, Goliasch, Georg, Hülsmann, Martin   +4 more
openaire   +5 more sources

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Neprilysin is a metalloprotease involved in proteolysis of numerous peptides, including natriuretic peptides, and is of prognostic and therapeutic importance in heart failure with reduced ejection fraction.
Yogesh N. V. Reddy, Seethalakshmi R. Iyer, Christopher G. Scott, Richard J. Rodeheffer, Kent Bailey, Gregory Jenkins, Anthony Batzler, Margaret M. Redfield, John C. Burnett, Naveen L. Pereira   +9 more
doaj   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian, Damman, Kevin, Desai, Akshay S., Gori, Mauro, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Prescott, Margaret F., Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +14 more
core   +4 more sources

Association between soluble neprilysin and diabetes: Findings from a prospective longitudinal study

Frontiers in Endocrinology, 2023
BackgroundThe potential role of neprilysin (NEP) in glucose metabolism has been found by basic studies but lacks population evidence. The objective of this study was to examine the association between serum NEP and diabetes in Chinese adults.MethodsIn a ...
Junting Hu, Hanyun Zhu, Yunlang Dai, Yang Liu, Ying Lu, Shasha Zhu, Linan Chen, Mingzhi Zhang, Tingbo Jiang, Hao Peng, Hao Peng   +10 more
doaj   +1 more source

Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]

, 2016
Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L., Desai, Akshay S., Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rouleau, Jean L., Shi, Victor, Solomon, Scott D., Starling, Randall, Swedberg, Karl, Teerlink, John, Zile, Michael R.   +11 more
core   +2 more sources

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]

, 2016
BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C., Baxter, A., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., Dayanandan, R., Emberson, J., Haynes, R., Herrington, W.G., Hill, M., Judge, P.K., Kalra, P.A., Knott, C., Landray, M.J., McMurray, John J., Murphy, K., Roderick, P., Staplin, N., Storey, B.C., Taal, M., Tomson, C., Wheatley, K., Wheeler, D.C.   +23 more
core   +1 more source